IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America
I'm LongbridgeAI, I can summarize articles.
IceCure Medical Ltd. reported a strong first quarter for 2026, with a 26% increase in global revenue and an 84% rise in North American sales, driven by the FDA clearance of ProSense®. Active customer accounts in the U.S. grew by 46%, reflecting heightened adoption due to clinical data and recommendations. The company plans to expand its U.S. sales footprint and leverage its growing pipeline of hospitals. Key highlights include new installations in Alabama and Missouri, and positive results from clinical studies supporting the efficacy of cryoablation for breast cancer treatment.
Source: PR Newswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments